NM Diabetes
Agenda
| 7:00am | Registration, Breakfast in Exhibit Area |
| 7:55am | Welcome and Introduction |
| 8:00am | Update on the Epidemiology of Type 2 Diabetes Mellitus (T2DM) in New Mexico, West Texas, the U.S., and Worldwide |
| 8:15am | Nutrition Therapy Recommendations |
| 9:00am | Evidence-Based Guidelines for Managing Patients with Obesity |
| 9:30am | Managing Comorbid Conditions: Focus on Cardiovascular Complications and Kidney Disease |
| 10:00am | Break, Refreshments in Exhibit Area |
| 10:30am | Pharmacology Update: Overview of Drug Classes, Treatment Options, Guidelines, and the Emergence of Biosimilar Agents |
| 11:15am | Individualizing Treatment Selection: Current Evidence for the Synergistic Use of Newer and Conventional Therapies to Improve Adherence, Glycemic Control, and Cardiometabolic Risk |
| 12:30pm | Q&A Panel Discussion |
| 1:00pm | Adjourn |
Target Audience
This activity is designed for family practice and other primary care physicians, endocrinologists, nurse practitioners, physician assistants, registered nurses, certified diabetes educators, registered dietitians, and other healthcare professionals who care for patients with type 2 diabetes.
Learning Objectives
At the conclusion of this activity, participants should be better able to:
- Recognize current statistics and future projections for type 2 diabetes mellitus (T2DM) in New Mexico, West Texas, the U.S. and worldwide.
- Review and apply concepts of nutrition therapy to improve diet and weight loss in patients with T2DM.
- Utilize recent evidence-based guidelines for managing obesity, including pharmacologic, non-pharmacologic and bariatric surgery options.
- Explain the increased risk of cardiovascular and kidney disease in patients with diabetes and utilize current treatment recommendations to prevent adverse events.
- Review current pharmacotherapy for the treatment of T2DM, including drug classes, treatment options, guidelines, and the emergence of biosimilar agents.
- Describe the pharmacokinetics and pharmacodynamics of emerging insulin and non-insulin therapies, and apply current evidence for their use in clinical practice.
Activity Goal/Desired Result
Improved clinical performance through increased knowledge and practice-based utilization of current evidence-based treatments and guidelines, and nutrition therapy recommendations. Greater recognition and management of factors that have an impact on managing T2DM, including lifestyle, obesity, cardiovascular risk, and diabetic kidney disease.
Summary of Identified Practice Gaps and Educational Needs
Currently in the U.S. nearly 50% of adults have diabetes or pre-diabetes, and if trends continue it is projected that one in three Americans will have diabetes by 2050. Obesity or being overweight remains the number one risk factor for T2DM. In 2014, New Mexico was ranked 11th and Texas 17th in the top 20 states that reported diabetes as an obesity-related health issue.
In recent years, the FDA has approved several novel agents, including one biosimilar insulin, for the management of T2DM and co-existing conditions. These include combination therapies, long-acting formulations, and the new SGLT2 inhibitors with a unique mechanism of action. There have also been advances in the treatment of obesity to be used in conjunction with lifestyle modifications.
Nutrition therapy continues to evolve and is a key component of diabetes management, however, basic principles are poorly understood by both clinicians and their patients. Current recommendations are highly effective when individualized for each patient based on factors such as health goals, culture, access to healthful choices, and readiness to change.
The 3rd Annual New Mexico Regional Diabetes Symposium will present current information, updated guidelines, and evidence-based strategies on these topics. Clinicians will assess case studies using an interactive audience response system to increase knowledge, improve competence, and help facilitate change in performance and professional practice.
CME Accreditation and Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of St. Joseph’s Hospital and Medical Center, and MandatoryCE. St. Joseph’s Hospital and Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
St. Joseph’s Hospital and Medical Center designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAFP CME Credit
This Live activity, 3rd Annual New Mexico Regional Diabetes Symposium, from 09/24/2016 - 10/29/2016, has been reviewed and is acceptable for up to 4.50 Prescribed credit(s) by the American Academy of Family Physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit
Dignity Health Arizona Region is an approved provider of continuing nursing education by the Western Multi-State Division, an accredited approver of the American Nurses Credentialing Center’s Commission on Accreditation.
(4.5 contact hours)
CDR Credit
This activity has been approved by the Commission on Dietetic Registration for 4.5 CPEUs.
Faculty Bios and Disclosures
Roberto Ruiz, MD, FACP
Dr. Roberto Ruiz is a Doctor of Internal Medicine, as well as a Board Certified Internal Medicine Specialist. He is Diplomate of the American Board of Internal Medicine and a Fellow at the American College of Physicians. He operates his own practice; the Southwest Internal Medicine Group in Phoenix, Arizona. Dr. Ruiz has been awarded recognition the past three years by the National Committee for Quality Assurance (NCQA), Diabetes Physician Recognition Program (DPRP). He has also been awarded for the past three years by the National Committee for Quality Assurance (NCQA), and the American Heart Association/American Stroke Association by the Heart/Stroke Recognition Program (HSRP). Since July 2008 his practice has been awarded recognition as an accredited Echocardiography Laboratory by the Intersocietal Commission for Accreditation of Echocardiography Laboratories (ICAEL).
He received his Doctor of Medicine at the Autonomous University of Guadalajara, Jalisco, Mexico 1975 to 1979 and did his Internship and Residency at Catholic Medical Center of Brooklyn, affiliated with Cornell Medical School. He has 25 years professional experience as a Physician and Medical Director at St. Lukes Hospital, Physician Vascular Diagnostic Inc., International Medical Association Group and Del Carmel Hospital in Jalisco Mexico. He is presently an Adjunct Assistant Professor, Clinical Division, Midwestern University Arizona College of Osteopathic Medicine and serves on the Advisory Board of the College of Nursing, Grand Canyon University since 2005. In 2010, Dr. Ruiz accepted the position of Clinical Assistant Professor at University of Arizona, College of Medicine-Phoenix Campus. Dr. Ruiz also accepted the position of an Assistant Clinical Professor at Creighton University College of Medicine-Phoenix St. Joseph’s campus in 2012.
Disclosure: Roberto Ruiz, MD, FACP
Consultant: AstraZeneca
Speakers Bureau: Janssen, Kowa, Merck
Philip Levy, MD, MACE
Dr. Levy is a clinical professor of medicine at the University of Arizona College of Medicine, and is chairman of the Section of Endocrinology and Metabolism at Banner Good Samaritan Regional Medical Center in Phoenix, Arizona, as well as past chief of staff and past chairman of medicine. He has practiced clinical endocrinology at Phoenix Endocrinology Clinic, LTD in Phoenix for more than 40 years. Dr. Levy graduated from the University of Pittsburgh School of Medicine in Pittsburgh, PA. He completed his internship, internal medicine residency, and fellowship in metabolism and endocrinology at Michael Reese Hospital and Medical Center in Chicago, Illinois. Dr. Levy was a research fellow in endocrinology at Guy’s Hospital Medical Center in London, England.
Dr. Levy served on the American Association of Clinical Endocrinologists (AACE) Board of Directors for six years, is past president of the American College of Endocrinology and currently serves as editor-in-chief of The First Messenger. He is past president and founding member of the board of directors of the Arizona Diabetes Association (ADA). Dr. Levy is an active member of AACE, American Medical Association and ADA in numerous capacities. He is a past member of The American Diabetes Association Board of Directors. He is also an Arizona Division of Motor Vehicles Medical Advisory Board Member, member of the Arizona Blue Shield, The Endocrine Society, American College of Physicians, Society of Nuclear Medicine, Arizona Medical Association, Clinical Endocrinology Editorial Board, and Endocrine Today Editorial Board. Dr. Levy is former Diabetes Forecast editor in chief and Clinical Diabetes editorial board member. He is a past editorial board member of Endocrine Practice. He is also a life member of the National Registry of Who’s Who.
Dr. Levy was presented the AACE Yank D. Coble, Jr., M.D., Distinguished Service Award in 2000 and the Master of the American College of Endocrinology Award in 2008.
Disclosure: Philip Levy, MD, MACE
Speakers Bureau: AstraZeneca, Boehringer-Ingelheim, Janssen, Novo Nordisk
W. Timothy Garvey, MD, FACE
Dr. Garvey is Professor of Medicine, Chair of the Department of Nutrition Sciences, and Director of the UAB Diabetes Research Center at the University of Alabama at Birmingham. He obtained his MD degree, cum laude, from St. Louis University in 1978, and completed residency training in Internal Medicine at Barnes Hospital, Washington University, in 1981. He then was a clinical fellow in Endocrinology and Metabolism at the University of Colorado Health Sciences Center and University of California, San Diego School of Medicine. He subsequently held faculty posts at the University of California, School of Medicine (Assistant Professor), Indiana University School of Medicine (Associate and full Professor), and from 1994 to 2003 was the Director of the Division of Endocrinology, Diabetes, and Medical Genetics at the Medical University of South Carolina. Dr. Garvey moved to UAB on June 1, 2004.
Dr. Garvey has achieved international recognition for his research in the metabolic, molecular, and genetic pathogenesis of insulin resistance, Type 2 Diabetes, and obesity. His studies have involved the cellular and molecular biology of cell and animal models, metabolic investigations of human subjects on metabolic research wards, and the genetic basis of diseases in Gullah-speaking African Americans and other national cohorts of diabetes patients. He has brought basic technology directly to the study of human patients, and the combined approach of human physiology, genetics, and basic cell and molecular biology has provided the laboratory with a flexible capability for hypothesis testing relevant to human disease. By studying molecular parameters and differential gene expression in muscle and fat tissue from metabolically characterized individuals, the Garvey laboratory has made important observations regarding the pathogenesis of human insulin resistance. He has been a principle contributor to our understanding of the role of the glucose transport system and glucose transporter proteins in human insulin resistance, and the role of adiponectin in the metabolic syndrome. He has identified gene families that contribute to insulin resistance in human muscle insulin using cDNA microarray, e.g., NR4A orphan nuclear receptors and the tribbles gene family, and is using mitochondrial proteomics to better define mitochondrial defects that impair substrate oxidation.
Dr. Garvey has directed an independent laboratory since 1987 supported by the National Institutes of Health (NIDDK, NHLBI), the Department of Veterans Affairs, the AHA, JDFI, the ADA, and other agencies. He has served as the PI of the NIH-funded Diabetes Research Center since its initiation in 2008. Dr. Garvey currently serves on the editorial boards of the Diabetes Care, Metabolic Syndrome & Related Disorders, Cardiorenal Medicine, and Journal of Clinical Endocrinology and Metabolism. He is a member of the American Society for Clinical Investigation, the Association of American Physicians, the Endocrine Society, the American Diabetes Association, the Obesity Society, and the American Association of Clinical Endocrinologists.
Disclosure: W. Timothy Garvey, MD, FACE
Consulting Fees/Advisory Boards: AstraZeneca, Eisai, Janssen, Novo Nordisk, Vivus, Takeda, Alexion, Merck
Research: Merck, Novo Nordisk, Pfizer, Sanofi, Eisai, AstraZeneca, Lexicon, Weight Watchers, Elcelyx
Pablo Mora, MD, MSc, FACE, CDE
Dr. Mora completed his undergraduate and graduate medical education at the University of Costa Rica School of Medicine. He completed postgraduate studies in internal medicine at the University of Costa Rica and University Hospitals in San Jose, Costa Rica where he also completed a critical care fellowship. He then went on to complete a fellowship in endocrinology and metabolism at the University of Texas Southwestern Medical Center in Dallas, Texas.
After graduation, Dr. Mora worked as Internal Medicine Staff at Parkland Memorial Hospital in Dallas and in 2001, joined the University of Texas Southwestern Medical School faculty, where he remained until 2012 with the rank of Associate Professor of Medicine. He accepted a position as staff Endocrinologist with the Department of Endocrinology of the Cleveland Clinic in Weston, Florida until June 2013.
Currently, he is a practicing Endocrinologist with Diabetes America in Plano, Texas and holds an appointment as Clinical Associate Professor with the Division of Endocrinology, Diabetes and Metabolism at the University of Texas Southwestern Medical Center in Dallas, Texas.
Dr. Mora is a Certified Diabetes Educator and a fellow of the American College of Clinical Endocrinologists. His clinical interests include diabetes in special populations, post-transplantation diabetes, and modern insulin therapy.
Disclosure: Pablo Mora, MD, MSc, FACE, CDE
Consultant: Novo Nordisk
Speaker's Bureau: AstraZeneca, Merck, Novo Nordisk
Deborah Hinnen, APN, BC-ADM, CDE, FAAN, FAADE
Has been a clinician and diabetes educator for over thirty years. As an advanced practice nurse, Debbie currently works at Memorial Hospital, University of Colorado Health, in Colorado Springs as the prescriber for a multidisciplinary team. Their program includes an ADA recognized comprehensive self-management program with day, evening and gestational classes. Pump and sensor services are available as well. Debbie helps provide clinical care and teaches evening classes for adults with T1 and T2 diabetes.
Debbie is involved extensively with the American Association of Diabetes Educators, having served as their national President. She was awarded the prestigious Distinguished Service Award and was honored with their “Fellow” designation. Debbie was also inducted as a Fellow into the American Academy of Nursing in 2003.
She has also served on the national board of directors for the American Diabetes Association, and is now on the editorial board for Clinical Diabetes. Currently Debbie serves on the ADA board for Southern Colorado.
She has served as faculty with the School of Pharmacy at the University of Kansas and Creighton, the Graduate Nursing Department and Physician Assistant Program at Wichita State University. In addition to clinical and academic efforts, Debbie publishes and speaks nationally and internationally. Most importantly, she is a Yia Yia (grandmother). Just ask if she has any cute pictures of Gar and Charlie.
Disclosure: Debbie Hinnen APN, BC-ADM, CDE, FAAN, FAADE
Honorarium/Expenses: AstraZeneca, CeQur, Janssen, Lilly/Boehringer Ingelheim, Novo Nordisk, Roche, Sanofi
Consultant: CeQur, Janssen, Lilly/Boehringer Ingelheim, Roche, Sanofi
Speakers's Bureau: AstraZeneca, Janssen, Lilly/Boehringer Ingelheim, Novo Nordisk, Roche, Sanofi
Linda Delahanty, MS, RD
Is Chief Dietitian and Director of Nutrition and Behavioral Research at Massachusetts General Hospital’s Diabetes Center and an Assistant Professor of Medicine at Harvard Medical School. She is a nationally recognized authority on nutrition and lifestyle interventions for the treatment of diabetes and obesity. She was a recipient of the National Award for Excellence in the Practice of Dietetics Research and the Medallion Award for lifetime achievement in the dietetics profession from the Academy of Nutrition and Dietetics and received the American Diabetes Association’s Outstanding Educator in Diabetes Award in 2015.
Ms. Delahanty has been a co-investigator in four NIH-funded multi-center clinical trials. She was chair of the Dietitians Committee for the landmark Diabetes Control and Complications Trial and was one of the architects of the lifestyle interventions for the Diabetes Control and Complications Trial, the Diabetes Prevention Program, Look AHEAD and the TODAY study. She has also conducted outcomes research on the cost effectiveness of medical nutrition therapy, predictors of weight outcomes and the translation of lifestyle interventions into primary care. Ms. Delahanty is currently one of the Principal Investigators for the NIH-funded REAL HEALTH Diabetes study to translate the Look AHEAD lifestyle intervention into primary care. She has authored both professional and lay articles on the role of nutrition and lifestyle in achieving weight loss and improved glycemic control and has been providing medical nutrition therapy to patients for diabetes and weight management for over 30 years. Linda is a graduate of the University of Massachusetts – Amherst and received a master’s degree from Boston University.
Disclosure: Linda Delahanty, MS, RD
Consultant: JanaCare
Advisory Board: JanaCare, Janssen, Lilly, Nutrisystem, Omada Health
Planning Committee
The following Planning Committee Members have stated they have nothing to disclose:
Richard Vanderpool, CHCP
Erica Brown
Veronica Baez
Katherine Jorgensen, MSN/MBA, RN-BC, RNC-NIC, Hon.D
Valerie Romero-Leggott, MD
Disclosure: Julie Crider, PhD
Consultant: Ocular Therapeutix, Farmigea, Regeneron, NovaBay, Pulmonx
Special Needs and ADA Compliance
Persons with special needs or a disability may request a reasonable accommodation, such as a dietary choices, sign language interpreter, etc., by contacting Richard Vanderpool at 888-YourCE1 (888-968-7231) or richard@mandatoryce.com. Requests should be made as early as possible to allow time to arrange the accommodation.
Email Article